DNA vs ILMN: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

ILMN is the larger of the two ($32.61B market cap): the incumbent the market prices for continued execution (34.88x forward earnings, beta 1.45). DNA is the smaller challenger ($805.73M), priced similarly on forward earnings (-4.13x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

DNA vs ILMN: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricDNAILMNWhat it tells you
Market cap$805.73M$32.61BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-4.1334.88Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta1.741.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range51% of range52% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book1.9510.42How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how DNA and ILMN affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DNA and ILMN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DNA and ILMN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ginkgo Bioworks Holdings (DNA) do?

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) is a synthetic-biology company built around a horizontal cell-programming platform. Historically it reported in two segments: Cell Engineering, where its automated Foundry labs and Datapoints data service engineer and characterize cells for pharma, agriculture, food, and industrial customers; and Biosecurity, which provided pathogen monitoring and bioinformatics to governments and institutions. Cell Engineering revenue is generated through R&D service fees, its Datapoints biological-data offerings, and design, build, and support fees for its lab-automation (RAC) systems. Ginkgo went public via SPAC in 2021 at a lofty valuation that has since collapsed.

Full DNA guide

What does Illumina (ILMN) do?

Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. Its business follows a razor-and-blades model: instruments such as the high-throughput NovaSeq X, the NextSeq, and the benchtop MiSeq seed an installed base, and the bulk of revenue then comes from recurring sequencing consumables (reagents and flow cells), which historically make up the majority of sales. The company is also pushing into multiomics, proteomics, and clinical diagnostics to expand what its platforms can measure. Illumina is headquartered in San Diego, was founded in 1998, and is led by CEO Jacob Thaysen.

Full ILMN guide

DNA vs ILMN: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • DNA drivers: AI, autonomous labs, and Datapoints; Cost restructuring toward breakeven.
  • ILMN drivers: Installed base and the consumables annuity; The NovaSeq X transition.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. For ILMN, competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share.

DNA or ILMN: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DNA if you believe its drivers more; ILMN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DNA and ILMN guides.

DNA vs ILMN: the full fundamentals

DNA. Ginkgo trades at about 5.4 times trailing sales with no earnings, so the valuation rests on whether revenue stabilizes near the ~$20 million quarterly run rate and losses keep shrinking toward the breakeven target. The stock is up about 21% in 2026 and about 34% over the past month on autonomous-lab and Datapoints news, but it remains down about 30% over the past year and sits well below its 52-week high of $18.22. Figures are from Yahoo Finance as of October 16, 2026; verify live numbers before acting.

ILMN. Illumina's multiple has expanded far faster than its earnings: the shares are up about 94% year to date and 172% over a year, while consensus calls for 2026 revenue growth near 11% and EPS of about $5.36. At roughly 43 times forward earnings and 36 times EV/EBITDA, the price assumes growth and margin expansion continue well beyond 2026, and the stock sits above the $241 average analyst target even as individual targets, such as JPMorgan's move to $320, have risen.

Headline figures (approximate, October 2026): DNA shows revenue (ttm) ~$132 million, with Q2 2026 revenue of ~$20 million down ~48% year over year, gross margin ~68%, while operating margin is deeply negative at about -285%, net loss (ttm) ~$310 million; Q2 2026 loss narrowed to ~$47 million from ~$83 million in Q1, eps (ttm / forward) ~-$5.06 trailing; consensus ~-$2.93 for 2026; ILMN shows revenue (ttm) ~$4.49 billion; Q2 2026 revenue ~$1.16 billion, up ~9% year over year, 2026 revenue consensus ~$4.62 billion (~11% growth); 2027 consensus ~$4.92 billion, margins (ttm) Gross ~68%, operating ~21%, net ~18%, net income and eps (ttm) ~$824 million net income; EPS ~$5.39 trailing, ~$6.12 forward.

The bottom line: DNA vs ILMN

DNA and ILMN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DNA and ILMN exposure against your real portfolio. It is not an investment adviser.

Wondering how DNA or ILMN fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ginkgo Bioworks Holdings

Ask Walnut's AI anything about DNA and see how it fits what you own.

FAQ

What is the difference between DNA and ILMN?

+

Ginkgo Bioworks Holdings, Inc. Illumina designs, makes, and sells next-generation DNA sequencing systems and the consumables that run on them, serving research, clinical, and applied-genomics customers. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is DNA or ILMN the better stock?

+

Neither is universally better. ILMN is the larger incumbent; DNA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, DNA or ILMN?

+

On forward P/E (as of November 2026), DNA trades at -4.13x and ILMN at 34.88x, so DNA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both DNA and ILMN?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of DNA vs ILMN?

+

DNA: The dominant risk is cash burn against an uncertain path to profitability: Ginkgo remains deeply unprofitable, revenue has kept falling year over year (Q2 2026 revenue was down about 48%), and it is spending down its cash (about $302 million at June 30, 2026, against about $404 million of debt including leases) while promising breakeven that has not yet arrived. If losses persist, further capital raises could dilute existing shareholders, and the company already completed a 1-for-40 reverse split after its post-SPAC valuation collapsed by billions, a reminder of how far expectations have reset. Customer concentration is a concern because a handful of large partners can drive results, and losing or delaying programs hits revenue hard. Competition spans synthetic-biology, lab-automation, and bio-AI players with more focus or funding. Execution risk on the autonomous-lab pivot is high, and the stock is speculative and volatile, so outcomes could be very good or very poor. Wall Street coverage is thin and skeptical: the two analysts in the Yahoo Finance consensus rate it underperform with a mean target near $8, below the October 16 close of $10.53. ILMN: Competition is intensifying: Ultima Genomics markets bulk whole-genome sequencing near $80 a genome, Element Biosciences' AVITI undercuts benchtop economics, and PacBio and Oxford Nanopore hold long-read niches, all pressuring Illumina's pricing and share. The underlying sequencing market is growing slowly, and soft academic and research funding, including pressure on US research budgets, can delay instrument purchases. China is now only about 3% of revenue after Illumina was effectively shut out of that market, where domestic players BGI and MGI dominate. Tariffs and a relatively high valuation add further risk. Valuation is now a larger part of the risk: at about 48 times trailing earnings and roughly 8.8 times sales after a 94% gain in 2026, the stock trades above the average analyst target of about $241, and the consensus for the third quarter calls for EPS of about $1.36 on revenue of about $1.15 billion, roughly 1% growth. A recall listing for the NovaSeq 6000Dx server correction is a reminder that clinical instruments carry regulatory exposure.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell DNA or ILMN; figures are approximate and dated (as of November 2026). Verify current data before investing.